Cytek director exercises 43,973 RSUs into shares
Cytek Biosciences director Jack Ball exercised a vested equity award for 43,973 shares of common stock through conversion of Restricted Stock Units.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cytek Biosciences director Jack Ball exercised a vested equity award for 43,973 shares of common stock through conversion of Restricted Stock Units. The RSU award fully vested on June 10, 2026, and after this non‑market, compensation-related transaction he directly holds 86,678 shares of Cytek common stock.
Insider Trade Summary
43,973 shares exercised/converted
Exercise
2 txns
Insider
Ball Jack
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 43,973 | $0.00 | $0.00 |
| Exercise | Common Stock | 43,973 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 contracts (Direct);
Common Stock — 86,678 shares (Direct)
Holdings Before and After:
Restricted Stock Units, 43,973 to 0 contracts (Direct);
Common Stock, 42,705 to 86,678 shares (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2. 100% of the shares subject to the RSU Award vested on June 10, 2026.
Key Figures
RSUs converted: 43,973 shares
Holding after transaction: 86,678 shares
RSU-to-share ratio: 1:1
+2 more
5 metrics
RSUs converted
43,973 shares
Restricted Stock Units converted into common stock on June 10, 2026
Holding after transaction
86,678 shares
Direct common stock holdings following RSU conversion
RSU-to-share ratio
1:1
Each RSU represents the right to receive one common share
RSU vesting
100% vested
All shares under the RSU award vested on June 10, 2026
Exercise price
$0.00 per share
Stated transaction price per share for RSU conversion
Key Terms
Restricted Stock Units, derivative security, contingent right, vesting
4 terms
Restricted Stock Units financial
"The filing lists "Restricted Stock Units" as a derivative security title."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"The transaction code description is "Exercise or conversion of derivative security"."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each Restricted Stock Unit represents a contingent right to receive one share."
vesting financial
"100% of the shares subject to the RSU Award vested on June 10, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cytek Biosciences (CTKB) director Jack Ball report?
Jack Ball reported exercising 43,973 Restricted Stock Units into Cytek common stock. This conversion reflects vesting of a prior equity award rather than an open-market purchase or sale, and resulted in an increase in his directly held common stock shares.
Was Jack Ball’s Cytek Biosciences (CTKB) Form 4 a market buy or sell?
The Form 4 does not report any open-market buy or sell. It shows a derivative exercise where 43,973 Restricted Stock Units were converted into common stock at a stated price of $0.00 per share as a vesting-related, compensation transaction.
What happened to Jack Ball’s Restricted Stock Units in this Cytek Biosciences (CTKB) filing?
The filing shows 43,973 Restricted Stock Units converted into common stock, leaving zero RSUs from that award outstanding. Footnotes state that 100% of the shares subject to the RSU award vested on June 10, 2026, triggering this conversion.
What does the Form 4 reveal about Cytek Biosciences (CTKB) RSU award terms?
The Form 4 states each Restricted Stock Unit represents a contingent right to receive one share of Cytek common stock. It also notes that 100% of the shares subject to Jack Ball’s RSU award vested on June 10, 2026, leading to share delivery.
AI-generated analysis. How Rhea-AI works. Not financial advice.
